Creating first in class cachexia therapeutic.

Creating a new standard of care for cancer cachexia patients, enabling greater tolerability of cancer treatment, lengthening life and improving quality of life.


Endevica Bio's lead drug candidate is a peptide therapeutic for treating cachexia due to cancer and other chronic conditions. The company was formed in 2009 to create best in class peptide drug candidates with better safety and efficacy properties than other drugs in the same class.


Endevica Bio's technology platform, protected by a family of patents and pending applications, allows us to modify peptides to perform better as drug candidates, with improved half-life, oral activity, and ability to cross the blood-brain barrier. One of TCI Peptide's core competencies is collaborating with other companies and institutions to reengineer peptides to be have better drug properties


The IND enabling toxicology program is underway for TCMCB07, Endevica Bio's cancer cachexia therapeutic. An IND is anticipated 1st quarter 2022. Next generation cachexia therapeutic molecule are being developed and tested. Additional molecules from the platform are being tested for new indications, including Duchenne Muscular Dystrophy and Type 2 Diabetes.

Major Milestones

NCI/NIH Grant Support

The National Cancer Institute continues to fund our underpinning research in cancer cachexia.


The company recently closed on a Series A financing.

Intellectual Property

Three issued patent and four pending patents protect our technology platform.

IND Program Begun

An IND enabling toxicology program has begun with an IND anticipated in Q4 2021.

Scroll to Top